A5063421851- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Venous Thromboembolism Diagnosis and Management
- Blood properties and coagulation
- Epigenetics and DNA Methylation
- Hemostasis and retained surgical items
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Vitamin K Research Studies
- Hemoglobinopathies and Related Disorders
University of Lausanne
2020-2025
University Hospital of Lausanne
2024
Emicizumab is a bispecific antibody mimicking coagulation factor VIII (FVIII) employed to treat patients with hemophilia A (PwHA) regardless of FVIII inhibitor status. The identification biological markers reflecting the hemostatic competence under emicizumab therapy would have great clinical value. Unfortunately, over-corrects standard assays, precluding their use for evaluating correction achieved in vivo. Here, we investigated whether global assays (GCA) allow monitoring response...
Abstract Background In factor XI (FXI) deficiency, bleeding cannot be predicted by routine analyses. Since FXI is involved in tissue (TF)-independent propagation loop of coagulation, we hypothesized that investigating the spatiotemporal separated phases coagulation (TF-dependent and -independent) could improve diagnostics. Objectives This article investigates correlation parameters describing TF-dependent -independent with clinical phenotype deficiency their ability to assess hemostasis...
Patients affected by the rare Glanzmann thrombasthenia (GT) suffer from defective or low levels of platelet-associated glycoprotein (GP) IIb/IIIa, which acts as a fibrinogen receptor, and have therefore an impaired ability to aggregate platelets. Because procoagulant activity is dichotomous facet platelet activation, diverging aggregation endpoint, we were interested in characterizing generate platelets GT patients. Therefore, investigated, flow cytometry analysis, functions three patients...
( Am J Obstet Gynecol . 2023;257–260) Low–molecular-weight heparins (LMWH) are often used to induce prophylactic anticoagulation for patients who experience venous thromboembolism, thrombophilia, and obstetrical antiphospholipid syndrome. It is theorized that unfractionated heparin delivered intravenously may be a possible alternative the use of LMWH in pregnant patients.